Abstract
We describe in this paper that the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(β-Dribofuranosyl)- quinoline-3-carboxylic acid (compound A) inhibits the HIV-1 replication in human primary cells. We initially observed that compound A inhibited HIV-1 infection in peripheral blood mononuclear cells (PBMCs) in a dosedependent manner, resulting in an EC50 of 1.5 ± 0.5 μM and in a selective index of 1134. Likewise, compound A blocked HIV-1BA-L replication in macrophages in a dose-dependent manner, with an EC50 equal to 4.98 ± 0.9 μM. The replication of HIV-1 isolates from subtypes C and F was also inhibited by compound A with the same efficiency. Compound A inhibited an early event of the HIV-1 replicative cycle, since it prevented viral DNA synthesis in PBMCs exposed to HIV-1. Kinetic assays demonstrated that compound A inhibits the HIV-1 enzyme reverse transcriptase (RT) in dose-dependent manner, with a KI equal to 0.5 ± 0.04 μM. Using a panel of HIV-1 isolates harboring NNRTI resistance mutations, we found a low degree of cross-resistance between compound A and clinical available NNRTIs. In addition, compound A exhibited additive effects with the RT inhibitors AZT and nevirapine, and synergized with the protease inhibitor atazanavir. Our results encourage continuous studies about the kinetic impact of compound A towards different catalytic forms of RT enzyme, and suggest that our nucleoside represents a promising molecule for future antiretroviral drug design.
Keywords: HIV-1, reverse transcriptase, chloroxoquinolinic ribonucleoside, inhibitor
Current HIV Research
Title: The Compound 6-Chloro-1,4-Dihydro-4-Oxo-1-(β-D-Ribofuranosyl) Quinoline-3-Carboxylic Acid Inhibits HIV-1 Replication by Targeting the Enzyme Reverse Transcriptase
Volume: 6 Issue: 3
Author(s): Thiago Moreno L. Souza, Claudio Cesar Cirne-Santos, Diego Q. Rodrigues, Celina M. Abreu, Amilcar Tanuri, Vitor F. Ferreira, Isakelly Pereira Marques, Maria Cecilia Bastos Vieira de Souza, Carlos Frederico Leite Fontes, Izabel Chistina de Palmer Paixao Frugulhetti and Dumith Chequer Bou-Habib
Affiliation:
Keywords: HIV-1, reverse transcriptase, chloroxoquinolinic ribonucleoside, inhibitor
Abstract: We describe in this paper that the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(β-Dribofuranosyl)- quinoline-3-carboxylic acid (compound A) inhibits the HIV-1 replication in human primary cells. We initially observed that compound A inhibited HIV-1 infection in peripheral blood mononuclear cells (PBMCs) in a dosedependent manner, resulting in an EC50 of 1.5 ± 0.5 μM and in a selective index of 1134. Likewise, compound A blocked HIV-1BA-L replication in macrophages in a dose-dependent manner, with an EC50 equal to 4.98 ± 0.9 μM. The replication of HIV-1 isolates from subtypes C and F was also inhibited by compound A with the same efficiency. Compound A inhibited an early event of the HIV-1 replicative cycle, since it prevented viral DNA synthesis in PBMCs exposed to HIV-1. Kinetic assays demonstrated that compound A inhibits the HIV-1 enzyme reverse transcriptase (RT) in dose-dependent manner, with a KI equal to 0.5 ± 0.04 μM. Using a panel of HIV-1 isolates harboring NNRTI resistance mutations, we found a low degree of cross-resistance between compound A and clinical available NNRTIs. In addition, compound A exhibited additive effects with the RT inhibitors AZT and nevirapine, and synergized with the protease inhibitor atazanavir. Our results encourage continuous studies about the kinetic impact of compound A towards different catalytic forms of RT enzyme, and suggest that our nucleoside represents a promising molecule for future antiretroviral drug design.
Export Options
About this article
Cite this article as:
Souza L. Thiago Moreno, Cirne-Santos Cesar Claudio, Rodrigues Q. Diego, Abreu M. Celina, Tanuri Amilcar, Ferreira F. Vitor, Marques Pereira Isakelly, Bastos Vieira de Souza Cecilia Maria, Leite Fontes Frederico Carlos, de Palmer Paixao Frugulhetti Chistina Izabel and Bou-Habib Chequer Dumith, The Compound 6-Chloro-1,4-Dihydro-4-Oxo-1-(β-D-Ribofuranosyl) Quinoline-3-Carboxylic Acid Inhibits HIV-1 Replication by Targeting the Enzyme Reverse Transcriptase, Current HIV Research 2008; 6 (3) . https://dx.doi.org/10.2174/157016208784324930
DOI https://dx.doi.org/10.2174/157016208784324930 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Astrocytes: Targets for Neuroprotection in Stroke
Central Nervous System Agents in Medicinal Chemistry Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 1. Fundamental Concepts in Molecular Genetics
Current Psychiatry Reviews Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Approaches to the Synthesis of Aripiprazole – A New Generation Antypsychotic Drug
Mini-Reviews in Organic Chemistry Central and Peripheral Expression and Distribution of NUCB2/nesfatin-1
Current Pharmaceutical Design Glycosomal Targets for Anti-Trypanosomatid Drug Discovery
Current Medicinal Chemistry Supervised Disulfiram as Adjunct to Psychotherapy in Alcoholism Treatment
Current Pharmaceutical Design The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum- Induced Peripheral Neurotoxicity
Current Cancer Drug Targets Cerebral Amyloidoses: Molecular Pathways and Therapeutic Challenges
Current Medicinal Chemistry Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology A Mendelian Randomization Study on Infant Length and Type 2 Diabetes Mellitus Risk
Current Gene Therapy New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design Synthesis of New Harmine Isoxazoles and Evaluation of their Potential Anti-Alzheimer, Anti-inflammatory, and Anticancer Activities
Medicinal Chemistry Dual Receptor-Specific Peptides Modified Liposomes as VEGF siRNA Vector for Tumor-Targeting Therapy
Current Gene Therapy HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology Ligand-Gated Pentameric ion Channels, from Binding to Gating
Current Molecular Pharmacology Opioid Withdrawal Syndrome: Emerging Concepts and Novel Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Preface [Hot Topic:Pharmacology of Weight Regulation Guest (Editor: Jason C.G. Halford)]
Current Drug Targets